(S)-3-azido-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester | 913743-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-3-azido-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (3S,4S)-3-azido-4-fluoropyrrolidine-1-carboxylate
• CAS: 913743-06-3
• 化学式: C₉H₁₅FN₄O₂
• 分子量: 230.242
• InChiKey: KOCYWXFCVGAWAO-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  43.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-3-azido-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester 在 platinum(IV) oxide 、 氢气 作用下， 以 甲醇 为溶剂， 生成 (3S,4S)-3-氨基-4-氟-1-吡咯烷甲酸叔丁酯
  参考文献：
  名称：

  Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit

  摘要：

  Starting from a hit identified by focused screening, 3-aminopyrrolidine factor Xa inhibitors were designed. The binding mode as determined by X-ray structural analysis as well as the pharmacokinetic behaviour of selected compounds is discussed. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.12.025
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 sodium azide 、 二乙胺基三氟化硫 、 氯化铵 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 32.0h， 生成 (S)-3-azido-4-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

  摘要：

  Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective. Secondary oncogenic EGFR mutations account for approximately 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective. The discovery of PF-06459988 (1), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.(1) Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clinical candidate PF-06747775 (21), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties. Compound 21 is currently being evaluated in phase-I clinical trials of mutant EGFR driven NSCLC.

  DOI：

  10.1021/acs.jmedchem.6b01894

文献信息

• PURINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：US20150141402A1

  公开（公告）日：2015-05-21

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药用盐，其中Q、G、环A、环B、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24和m在此定义。这些新颖的嘌呤衍生物在治疗哺乳动物中的异常细胞生长，如癌症方面具有用途。另外，还涉及含有这些化合物的药物组合物，以及在治疗哺乳动物中的异常细胞生长方面使用这些化合物和组合物的方法。
• Cyclic amines
  申请人：Zbinden Groebke Katrin

  公开号：US20060247238A1

  公开（公告）日：2006-11-02

  The invention is concerned with cyclic amines of formula (I) wherein X 1 to X 3 , Y 1 to Y 3 , R 1′ , R 1″ and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments and for treating diseases associated with coagulation factor Xa.

  这项发明涉及公式(I)中的环氨基化合物，其中X1至X3，Y1至Y3，R1'，R1"和n如描述和索赔中定义的那样，以及其生理上可接受的盐。这些化合物抑制凝血因子Xa，并可用作药物治疗与凝血因子Xa相关的疾病。
• Fluorinated Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US20150118258A1

  公开（公告）日：2015-04-30

  The present invention relates to fluorinated bridged spiro[2.4]heptane derivatives of formula (I), wherein n and R 1 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  本发明涉及公式（I）中的氟化桥式螺[2.4]庚烷衍生物，其中n和R1如描述中所定义，它们的制备以及它们作为药物活性化合物的用途。
• BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160200686A1

  公开（公告）日：2016-07-14

  The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  本发明涉及公式（I）的苯并咪唑基甲基脲衍生物，其中n，D，E，R1，R2，R3，R4，R6，R7，R8和R9如说明书所定义，它们的制备以及它们作为药物活性化合物的用途。
• Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit
  作者：Katrin Groebke Zbinden、Lilli Anselm、David W. Banner、Jörg Benz、Francesca Blasco、Guillaume Décoret、Jacques Himber、Bernd Kuhn、Narendra Panday、Fabienne Ricklin

  DOI：10.1016/j.ejmech.2008.12.025

  日期：2009.7

  Starting from a hit identified by focused screening, 3-aminopyrrolidine factor Xa inhibitors were designed. The binding mode as determined by X-ray structural analysis as well as the pharmacokinetic behaviour of selected compounds is discussed. (C) 2009 Elsevier Masson SAS. All rights reserved.